Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Phase 2

Terminated

Conditions: Oral Mucositis

Interventions: Biological: ALD518
Drug: 0.9% saline

First Posted Date: 2011-07-27

Last Posted Date: 2021-05-11

Lead Sponsor: CSL Behring

Target Recruit Count: 76

Registration Number: NCT01403064

Locations: 🇺🇸
Morton Plant Mease Health Care, Clearwater, Florida, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States

and more 28 locations

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 4

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Biological: IgPro10

First Posted Date: 2011-07-11

Last Posted Date: 2016-04-08

Lead Sponsor: CSL Behring

Target Recruit Count: 57

Registration Number: NCT01390649

Locations: 🇧🇬
UMHAT "Dr. Georgi Stranski" Clinic of Haematology, Pleven, Bulgaria
🇧🇬
UMHAT "Sv. Georgi" Clinic of Haematology, Plovdiv, Bulgaria
🇧🇬
Tokuda Hospital, Sofia, Bulgaria

and more 14 locations

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: BMS-945429
Drug: BMS-945429 Placebo
Drug: Adalimumab
Drug: Methotrexate Placebo
Drug: Methotrexate
Drug: Adalimumab Placebo

First Posted Date: 2011-06-14

Last Posted Date: 2021-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 418

Registration Number: NCT01373151

Locations: 🇺🇸
Sun Valley Arthritis Center, Ltd., Peoria, Arizona, United States
🇺🇸
San Diego Arthritis Medical Clinic, San Diego, California, United States
🇺🇸
New England Research Associates, Llc, Trumbull, Connecticut, United States

and more 12 locations

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein

First Posted Date: 2011-05-26

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 17

Registration Number: NCT01361126

Locations: 🇮🇱
Study Site, Tel Aviv, Israel

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Biological: CR002 Liquid API
Biological: Placebo

First Posted Date: 2011-05-04

Last Posted Date: 2012-04-05

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01347190

Locations: 🇧🇬
Site 11, Sofia, Bulgaria
🇧🇬
Site 12, Varna, Bulgaria
🇭🇺
Site 30, Debrecen, Hungary

and more 8 locations

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein
Biological: Plasma derived FIX [pdFIX]

First Posted Date: 2010-11-03

Last Posted Date: 2012-01-31

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01233440

Locations: 🇮🇹
Study site, Milan, Italy
🇪🇸
Study Site, Madrid, Spain

Study of Biostate® in Children With Hemophilia A

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Biostate

First Posted Date: 2010-10-27

Last Posted Date: 2017-08-24

Lead Sponsor: CSL Behring

Target Recruit Count: 35

Registration Number: NCT01229007

Locations: 🇲🇽
Study site, Monterrey, Mexico
🇺🇦
Study Site, Lviv, Ukraine

Extension Study of Biostate in Subjects With Von Willebrand Disease

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Biostate

First Posted Date: 2010-10-20

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 20

Registration Number: NCT01224808

Locations: 🇺🇦
Study Site, Lviv, Ukraine

Study of Biostate® in Children With Von Willebrand Disease

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Biostate

First Posted Date: 2010-10-04

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 17

Registration Number: NCT01213446

Locations: 🇱🇧
Study site, Beirut, Lebanon
🇺🇦
Study Site, Lviv, Ukraine

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: Immune Globulin Subcutaneous (Human) (SCIG)

First Posted Date: 2010-09-13

Last Posted Date: 2014-12-12

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01199705

Locations: 🇯🇵
Study site, Tokorozawa city, Saitama Pref., Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy